NADNCT07132801
Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
A study testing Qualia NAD⁺ version 1, Qualia NAD⁺ version 2 and Qualia NAD⁺ version 3 in people with NAD and NAD+ Levels in the Blood, run by Qualia Life Sciences at 1 site in United States.
Trial summary
This is a double-blind, placebo-controlled, parallel-group study evaluating the effects of three distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Read more about this study
- Who is it for?
- Ages 35 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- NAD, NAD+ Levels in the Blood
- What is being tested?
- Qualia NAD⁺ version 1, Qualia NAD⁺ version 2 and Qualia NAD⁺ version 3
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 76 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Apr 2026to 5 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Provide voluntary, written, informed consent to participate in the study
- Agree to provide a valid cell phone number and are willing to receive communications through text
- Can read and write English
- Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
- Willing to complete questionnaires, records, and diaries associated with the study
- Healthy male and female participants aged 35-75 years
- Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28)
- Willing to avoid supplements, energy drinks/shots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for at least 2 weeks before baseline and throughout the study
Who cannot join
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
- Known food intolerances/allergy to any ingredients in the product
- Having any of the following conditions: psychiatric conditions, neurologic disorders, endocrine disorders, cancer
- Having had a significant cardiovascular event in the past 6 months
- Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
- On immunosuppressive therapy
- Individuals who were deemed incompatible with the test protocol
- Adults lacking capacity to consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Double-Blind, Placebo-Controlled Four-Arm Trial
This is a double-blind, placebo-controlled, parallel-group study evaluating the effects of three distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 76 participants will be assigned to one of four study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Read the detailed description
Design: double-blind, placebo-controlled, parallel-group trial with four arms (Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, and placebo) and 1:1:1:1 allocation, stratified by gender and age at screening. Participants are assigned to arms using systematic allocation. A designated Qualia Life Sciences staff member independent of the research team assigns and labels all study products as A, B, C, or D; participants and study personnel remain blinded to group assignment until all study data have been collected and finalized.
Participants take two capsules of their assigned product once daily in the morning, with or without food, for 28 consecutive days (a 28-day supply of 56 capsules). Intracellular NAD⁺ is measured with a self-administered dried-blood-spot finger-stick kit at baseline (Day 0) and at the end of supplementation (Day 28). The Aging Male/Female Symptom (AMFS) scale, RAND SF-36, and a Safety and Tolerability survey are completed electronically at baseline and on Days 7, 14, 21, and 28, with a post-study exit questionnaire on Day 32 and regular adherence and safety check-ins. All assessments are completed remotely; there are no in-person visits.
Between-group comparisons use linear mixed-effects models with fixed effects for group, time, and their interaction, accounting for repeated measures within participants; within-group changes from baseline use paired t-tests or linear mixed-effects models. Data that do not meet normality assumptions are analyzed with non-parametric tests.
Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. In the same update, this record was revised to match Protocol version 3, which added a third Qualia NAD⁺ formulation: the study has four arms (Qualia NAD⁺ version 1, version 2, version 3, and placebo) with approximately 76 participants, rather than the three arms and 180 participants described in earlier versions of this record. Outcome measures, dosing, and study duration are unchanged.
- Conditions
- NAD, NAD+ Levels in the Blood
- Being tested
- Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, Placebo
- Keywords
- NAD Supplementation, NAD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Qualia NAD⁺ version 1Dietary supplement
Qualia NAD+ version 1 manufactured by Qualia Life Sciences
Qualia NAD⁺ version 2Dietary supplement
Qualia NAD+ version 2 manufactured by Qualia Life Sciences
Qualia NAD⁺ version 3Dietary supplement
Qualia NAD+ version 3 manufactured by Qualia Life Sciences
PlaceboDietary supplement
Rice Flour
| Study group | Role | What they receive |
|---|---|---|
| Qualia NAD⁺ version 1 | Active comparator | Two capsules of Qualia NAD⁺ version 1 once daily in the morning, with or without food, for 28 consecutive days. Receives: Dietary Supplement: Qualia NAD⁺ version 1 |
| Qualia NAD⁺ version 2 | Active comparator | Two capsules of Qualia NAD⁺ version 2 once daily in the morning, with or without food, for 28 consecutive days. Receives: Dietary Supplement: Qualia NAD⁺ version 2 |
| Qualia NAD⁺ version 3 | Active comparator | Two capsules of Qualia NAD⁺ version 3 once daily in the morning, with or without food, for 28 consecutive days. Receives: Dietary Supplement: Qualia NAD⁺ version 3 |
| Placebo | Placebo comparator | Two capsules of placebo (inert rice powder in a vegetable/cellulose capsule, matched in appearance) once daily in the morning, with or without food, for 28 consecutive days. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Between-group change in intracellular NAD⁺ levels
To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, Qualia NAD version 3, or placebo.
Measured: 28 days
Secondary outcomes (4)
Aging-Related Symptoms (AMFS scores)
To evaluate within-group and between-group differences in the change in Aging Male/Female Symptom (AMFS) total and sub-scale scores.
Measured: 4 weeks
RAND SF-36 Scale Scores
To assess within-group and between-group differences in RAND SF-36 domain scores.
Measured: 4 weeks
Side effect profile as measured by a custom Safety and Tolerability survey
To evaluate side effect profiles using a custom Safety and Tolerability survey.
Measured: Week 1, 2, 3, and 4
Within-group differences in the change in intracellular NAD⁺ levels
To assess within-group differences in the change in intracellular NAD⁺ levels
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2025
- Study start22 Apr 2026
- Primary completion29 May 2026
- Study completion5 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NADStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 76 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qualia Life Sciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07132801
- Sponsor's protocol ID
- QLS-014
- Status last verified
- Oct 2026
- First submitted
- 13 Aug 2025
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Double-Blind, Placebo-Controlled Four-Arm Trial
- ClinicalTrials.gov ID
- NCT07132801
- Acronym / sponsor ID
- QLS-014
- Conditions
- NAD, NAD+ Levels in the Blood
- Keywords
- NAD Supplementation, NAD
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 76 participants (actual)
- Lead sponsor
- Qualia Life SciencesIndustry (pharma, biotech, devices)
- Study start
- 22 Apr 2026 (actual)
- Primary completion
- 29 May 2026 (actual)
- Study completion
- 5 Jun 2026 (actual)
- First posted
- 20 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double-blind, placebo-controlled, parallel-group study evaluating the effects of three distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 76 participants will be assigned to one of four study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Detailed description
Design: double-blind, placebo-controlled, parallel-group trial with four arms (Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, and placebo) and 1:1:1:1 allocation, stratified by gender and age at screening. Participants are assigned to arms using systematic allocation. A designated Qualia Life Sciences staff member independent of the research team assigns and labels all study products as A, B, C, or D; participants and study personnel remain blinded to group assignment until all study data have been collected and finalized.
Participants take two capsules of their assigned product once daily in the morning, with or without food, for 28 consecutive days (a 28-day supply of 56 capsules). Intracellular NAD⁺ is measured with a self-administered dried-blood-spot finger-stick kit at baseline (Day 0) and at the end of supplementation (Day 28). The Aging Male/Female Symptom (AMFS) scale, RAND SF-36, and a Safety and Tolerability survey are completed electronically at baseline and on Days 7, 14, 21, and 28, with a post-study exit questionnaire on Day 32 and regular adherence and safety check-ins. All assessments are completed remotely; there are no in-person visits.
Between-group comparisons use linear mixed-effects models with fixed effects for group, time, and their interaction, accounting for repeated measures within participants; within-group changes from baseline use paired t-tests or linear mixed-effects models. Data that do not meet normality assumptions are analyzed with non-parametric tests.
Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. In the same update, this record was revised to match Protocol version 3, which added a third Qualia NAD⁺ formulation: the study has four arms (Qualia NAD⁺ version 1, version 2, version 3, and placebo) with approximately 76 participants, rather than the three arms and 180 participants described in earlier versions of this record. Outcome measures, dosing, and study duration are unchanged.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Qualia NAD⁺ version 1 | Active comparator | Dietary Supplement: Qualia NAD⁺ version 1Two capsules of Qualia NAD⁺ version 1 once daily in the morning, with or without food, for 28 consecutive days. |
| Qualia NAD⁺ version 2 | Active comparator | Dietary Supplement: Qualia NAD⁺ version 2Two capsules of Qualia NAD⁺ version 2 once daily in the morning, with or without food, for 28 consecutive days. |
| Qualia NAD⁺ version 3 | Active comparator | Dietary Supplement: Qualia NAD⁺ version 3Two capsules of Qualia NAD⁺ version 3 once daily in the morning, with or without food, for 28 consecutive days. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboTwo capsules of placebo (inert rice powder in a vegetable/cellulose capsule, matched in appearance) once daily in the morning, with or without food, for 28 consecutive days. |
Who may qualify
- Ages
- 35 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Provide voluntary, written, informed consent to participate in the study
- Agree to provide a valid cell phone number and are willing to receive communications through text
- Can read and write English
- Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
- Willing to complete questionnaires, records, and diaries associated with the study
Key exclusion criteria (8 listed)
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
- Known food intolerances/allergy to any ingredients in the product
- Having any of the following conditions: psychiatric conditions, neurologic disorders, endocrine disorders, cancer
- Having had a significant cardiovascular event in the past 6 months
- Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Qualia NAD⁺ version 1Qualia NAD+ version 1 manufactured by Qualia Life Sciences | Dietary supplement | Qualia NAD⁺ version 1 |
| Qualia NAD⁺ version 2Qualia NAD+ version 2 manufactured by Qualia Life Sciences | Dietary supplement | Qualia NAD⁺ version 2 |
| Qualia NAD⁺ version 3Qualia NAD+ version 3 manufactured by Qualia Life Sciences | Dietary supplement | Qualia NAD⁺ version 3 |
| PlaceboRice Flour | Dietary supplement | Placebo |
Primary outcome
Between-group change in intracellular NAD⁺ levels
Time frame: 28 days
To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, Qualia NAD version 3, or placebo.
4 secondary outcomes
Aging-Related Symptoms (AMFS scores)
Time frame: 4 weeks
RAND SF-36 Scale Scores
Time frame: 4 weeks
Side effect profile as measured by a custom Safety and Tolerability survey
Time frame: Week 1, 2, 3, and 4
Within-group differences in the change in intracellular NAD⁺ levels
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for NAD
RecruitingPhase 1
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
NAD+ Metabolism, Pharmacokinetics
Recruiting
Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism
Healthy Adult
Not yet recruitingPhase 2
Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Recruiting
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Aging, Frailty
Not yet recruitingPhase 2
PEDIatric Cardiac Dysfunction Treated With Injectable Nicotinamide Adenine Dinucleotide
Cardiac Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Qualia NAD⁺ version 1, Qualia NAD⁺ version 2 and Qualia NAD⁺ version 3 in people with NAD and NAD+ Levels in the Blood, run by Qualia Life Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Between-group change in intracellular NAD⁺ levels (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.